Clinical Trials Logo

Filter by:
NCT ID: NCT05818020 Completed - Biologic Clinical Trials

Multidisciplinary Integrated Platform for a Technological Innvovative Approach to Oncotherapies

Start date: March 2, 2020
Phase:
Study type: Observational

This is multicentric, observational, and retro- prospective study.

NCT ID: NCT05817292 Completed - Vaginal Disease Clinical Trials

Study of the Vaginal Microbiota in Women Under Fertile Age

vaginalbiota
Start date: February 1, 2022
Phase:
Study type: Observational

Characterization of the vaginal microbiota of women under fertile age and study of correlations with gynecological disorders

NCT ID: NCT05817123 Completed - Clinical trials for Obstructive Sleep Apnea

Validation of the Mutuality Scale in Patients With OSA and Their Partners

VAMOS
Start date: May 10, 2021
Phase:
Study type: Observational

Main objective of this study is to assess the psychometric characteristics of the Mutuality Scale both in patients with Obstructive Sleep Apnea Syndrome (OSAS) and in their partners-The association between the mutuality score in OSAS patients and their adherence to the use of Continuous Positive Airway Pressure (CPAP) therapy will also be investigated. The results of the study may allow a validation of the Mutuality Score as an instrument for measuring mutuality between OSAS patients and their partners.

NCT ID: NCT05814302 Completed - Fever Clinical Trials

Treatment Of Fever In The Emergency Department

Start date: June 1, 2021
Phase:
Study type: Observational

Fever is a frequent cause of admission to the Emergency Department (ED) around the world. While it can be caused by a wide range of conditions, the most effective treatment based on its etiology is still undetermined. This observational, prospective, single-center study enrolled adult patients who accessed the ED for fever, with the aim to define the most effective treatment for them.

NCT ID: NCT05812846 Completed - Stroke Clinical Trials

Monitoring of the Ischemic Stroke Patient Through the Use of New Serum Biomarkers and MRI Imaging

Start date: December 4, 2018
Phase:
Study type: Observational

Aim of this study will be the evaluation (by ELISA quantification and quantitative RT-PCR) of circulating biomarkers of damage and regeneration in patients affected by ischemic stroke. The biomarker levels will be measured from the acute event (48h) and in subsequent 4 times (7 days, 30 days, 90 days, 180 days) following hospitalization, up to 6 months after the acute event. These data will then be correlated for all five times with the clinical scales normally used for patient evaluation and will also be associated with MRI-DTI measurements performed in the post-acute (30 days) and post-discharge (180 days) phase.

NCT ID: NCT05812521 Completed - Post Operative Pain Clinical Trials

Thoracic Paravertebral Block With Methylene Blue Visual Confirmation for Postoperative Pain After VATS Lobectomy

Start date: January 15, 2020
Phase: N/A
Study type: Interventional

The goal of this study is to compare the efficacy in controlling postoperative pain of paravertebral block (PVB) with methylene blue visual confirmation and thoracic epidural anesthesia (TEA). This is a single center, parallel-group, prospective study. Patients will be randomly assigned in a 1:1 ratio to receive either PVB or TEA. Primary end-point is pain relief measured with Postoperative Numeric Rating Scale. The secondary end-points are time to perform TEA and PVB, total opioid consumption, postoperative outcomes.

NCT ID: NCT05811689 Completed - Multiple Sclerosis Clinical Trials

Trabecular Bone Score in Multiple Sclerosis

Start date: February 14, 2021
Phase:
Study type: Observational

Assess bone quality in MS patients through TBS and evaluate the potential effects exerted by different drugs used in MS treatment, which may affect BMD and TBS in MS patients

NCT ID: NCT05810584 Completed - Orthopedic Disorder Clinical Trials

Revision LR Femoral Stem for Hip Replacement

Start date: June 4, 2021
Phase:
Study type: Observational

This is a post-market, monocentric Retrospective and prospective, observational, open-label and baseline clinical study in order to evaluate the performance and safety of Revision LR femoral stem

NCT ID: NCT05810441 Completed - Celiac Disease Clinical Trials

Intestinal Transglutaminase Antibodies in Celiac Disease Diagnosis

Start date: September 23, 2019
Phase:
Study type: Observational

Celiac disease (CD) is a systemic autoimmune gluten-dependent enteropathy in subjects with HLA DQ2/8. CD prevalence is more than 1% with a progression to 2% in adulthood. Among the group at risk such as first-degree relatives, subjects with autoimmune diseases (eg type 1 diabetes) or with syndromes (Down's disease, Turner) the prevalence reaches 5-8%. Recently, in pediatrics CD diagnostic criteria have been modified and the intestinal biopsy can be omitted in presence of a specific clinical and laboratory picture. In the remaining pediatric cases and in all adult patients, the biopsy is fundamental for the diagnosis. The clinical manifestation of CD not always depends on the enteropathy and on the related symptoms, but it can be characterized by extra-intestinal symptoms (eg chronic fatigue, anemia, arthralgia, cerebellar ataxia, alterations of dental enamel) that often hamper a rapid CD recognition delaying the diagnosis especially in adults. Symptoms are not always related to intestinal injury and may be present even when intestinal mucosa is normal. This condition is known as potential CD in which serum IgA anti-transglutaminase antibodies (anti-ttg) are generally positive at low concentrations (eg higher 2-3 times than the cut-off) or positive occasionally. In this clinical context, the gluten-free diet is an effective therapy able to improve the clinical picture and to stop the anti-ttg production. Recent observations, especially in pediatric field, have shown that in potential CD the immunological analysis of intestinal biopsies is characterized by the presence of anti-ttg deposits in the intestinal mucosa which predict the development of intestinal atrophy in a time span of 3- 5 years. Furthermore, these deposits disappear with the diet-therapy. In pediatric field, the diagnostic specificity of mucosal anti-ttg (anti-ttg-m) is between 95-98%, while the sensitivity is 100%. In adults, anti-ttg-m show 100% sensitivity in typical celiac disease (characterized by high serum anti-ttg concentrations and intestinal mucosa atrophy), while no results are available about potential celiac disease. Moreover, in adults data about the specificity of anti-ttg-m in infectious, oncological and inflammatory diseases of the gastro-intestinal tract are not available. The main study objectives are to evaluate anti-ttg-m sensitivity in patients with typical celiac disease and anti-ttg-m specificity in patients with oncological and inflammatory bowel diseases.

NCT ID: NCT05810285 Completed - Knee Osteoarthritis Clinical Trials

Total Knee Arthroplasty With Vitamin E Polyethylene

Start date: June 12, 2021
Phase:
Study type: Observational

The aim of this observational study is to investigate if there is any difference in survival rate, clinical and radiological results after total knee replacement with vitamin E-blended polyethylene in comparison to conventional polyethylene at minimum 7-year follow-up